Active site mapping, biochemical properties and subcellular localization of rhodesain, the major cysteine protease of Trypanosoma brucei rhodesiense.
Cysteine protease activity of African trypanosome parasites is a target for new chemotherapy using synthetic protease inhibitors. To support this effort and further characterize the enzyme, we expressed and purified rhodesain, the target protease of Trypanosoma brucei rhodesiense (MVAT4 strain), in reagent quantities from Pichia pastoris. Rhodesain was secreted as an active, mature protease. Site-directed mutagenesis of a cryptic glycosylation motif not previously identified allowed production of rhodesain suitable for crystallization. An invariable ER(A/V)FNAA motif in the pro-peptide sequence of rhodesain was identified as being unique to the genus Trypanosoma. Antibodies to rhodesain localized the protease in the lysosome and identified a 40-kDa protein in long slender forms of T. b. rhodesiense and all life-cycle stages of T. b. brucei. With the latter parasite, protease expression was five times greater in short stumpy trypanosomes than in the other stages. Radiolabeled active site-directed inhibitors identified brucipain as the major cysteine protease in T. b. brucei. Peptidomimetic vinyl sulfone and epoxide inhibitors designed to interact with the S2, S1 and S' subsites of the active site cleft revealed differences between rhodesain and the related trypanosome protease cruzain. Using fluorogenic dipeptidyl substrates, rhodesain and cruzain had acid pH optima, but unlike some mammalian cathepsins retained significant activity and stability up to pH 8.0, consistent with a possible extracellular function. S2 subsite mapping of rhodesain and cruzain with fluorogenic peptidyl substrates demonstrates that the presence of alanine rather than glutamate at S2 prevents rhodesain from cleaving substrates in which P2 is arginine.
Caffrey
C R
CR
Tropical Disease Research Unit, Department of Pathology, University of California San Francisco, VAMC, 4150 Clement Street-113B, San Francisco, CA 94121, USA.
Hansell
E
E
Lucas
K D
KD
Brinen
L S
LS
Alvarez Hernandez
A
A
Cheng
J
J
Gwaltney
S L
SL
Roush
W R
WR
Stierhof
Y D
YD
Bogyo
M
M
Steverding
D
D
McKerrow
J H
JH
D000818:Animals; D001665:Binding Sites / Q000235:genetics; D003546:Cysteine Endopeptidases / Q000737:chemistry / Q000235:genetics* / Q000302:isolation & purification / Q000378:metabolism*; D004852:Epoxy Compounds / Q000494:pharmacology; D008247:Lysosomes / Q000201:enzymology*; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D011480:Protease Inhibitors / Q000494:pharmacology; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism; D017422:Sequence Analysis, DNA; D013450:Sulfones / Q000494:pharmacology; D016833:Trypanosoma brucei rhodesiense / Q000201:enzymology* / Q000235:genetics / Q000254:growth & development
D004852:Epoxy Compounds; D011480:Protease Inhibitors; D011994:Recombinant Proteins; D013450:Sulfones; C009873:divinyl sulfone; D003546:Cysteine Endopeptidases; C446033:rhodesain